Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication-Reference-Cited by-同舟云学术

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Published:2018-02 Issue:2 Volume:26 Page:238-243
ISSN:1319-0164
Container-title:Saudi Pharmaceutical Journal
language:en
Short-container-title:Saudi Pharmaceutical Journal

Author:

Balkhi Bander,Seoane-Vazquez Enrique,Rodriguez-Monguio Rosa

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacology

Reference31 articles.

1. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study;Abrahamsen;J. Bone Miner. Res.,2009

2. Declining rates of osteoporosis management following fragility fractures in the US, 2000 through 2009;Balasubramanian;J. Bone Joint Surg. Am.,2014

3. The value of interrupted time-series experiments for community intervention research;Biglan;Prev. Sci.,2000

4. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention;Bock;J. Musculoskelet. Neuronal Interac.,2007

5. Relation of bisphosphonate therapies and risk of developing atrial fibrillation;Bunch;Am. J. Cardiol.,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug discovery;Translational Orthopedics;2024

2. Bisphosphonates for postmenopausal osteoporosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-09-28

3. Global burden of hip fracture: The Global Burden of Disease Study;Osteoporosis International;2023-09-14

4. Trends in Management of Osteoporosis Following Primary Vertebral Compression Fracture;Journal of the Endocrine Society;2023-06-05

5. Genome-wide association study of osteonecrosis of the jaw in Danish patients receiving antiresorptive therapy for osteoporosis: A case-control study;Bone Reports;2023-06